At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jun 18, 2026 at 08:00 ET
Denali Therapeutics announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in gross proceeds. The PRV was awarded following FDA approval of AVLAYAH for Hunter syndrome in March 2026. The non-dilutive cash infusion strengthens Denali's financial flexibility and will fund its clinical pipeline, including programs for lysosomal storage disorders and neurodegenerative diseases.
- Denali entered a definitive agreement to sell its Rare Pediatric Disease PRV for $195 million gross proceeds.
- The PRV was awarded after FDA accelerated approval of AVLAYAH (tividenofusp alfa-eknm) for Hunter syndrome in March 2026.
- Proceeds will support Denali's TransportVehicle-enabled clinical pipeline, including DNL126, DNL593, DNL952, and DNL628.
- The transaction is subject to customary closing conditions, including HSR Act waiting period expiration.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access